Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial.
Francioso S, Almerighi C, Forte P, Bandiera F, Nosotti L, Lionetti R, Taliani G, Piras MR, Ponti ML, Parruti G, Di Candilo F, Gentile S, Piccolo P, Salso A, Riccobelli F, Renzi S, Longo MA, Montalbano M, Zaru S, Biliotti E, Di Masi F, Santopaolo F, Angelico M. Francioso S, et al. Among authors: di candilo f. Dig Liver Dis. 2014 Feb;46(2):164-9. doi: 10.1016/j.dld.2013.10.002. Epub 2013 Nov 13. Dig Liver Dis. 2014. PMID: 24239044 Clinical Trial.
A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy.
Angelico M, Cepparulo M, Angelico F, Francioso S, Barlattani A, Di Candilo F, Della Vecchia R, Demelia L, De Sanctis G, Gentile S, Grieco A, Parruti G, Sabusco G, Tarquini L, Tosti A, Zaru S; SMIEC 1 GROUP. Angelico M, et al. Among authors: di candilo f. Aliment Pharmacol Ther. 2004 Feb 1;19(3):339-47. doi: 10.1111/j.1365-2036.2004.01843.x. Aliment Pharmacol Ther. 2004. PMID: 14984381 Clinical Trial.
May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics.
Tontodonati M, Cento V, Polilli E, Colabattista C, Cascella R, Sciotti M, Di Giammartino D, Trave F, Di Maio VC, Monarca R, Di Candilo F, Prinapori R, Rastrelli E, Vecchiet J, Ceccherini-Silberstein F, Manzoli L, Giardina E, Perno CF, Parruti G. Tontodonati M, et al. Among authors: di candilo f. New Microbiol. 2015 Oct;38(4):491-7. Epub 2015 Oct 20. New Microbiol. 2015. PMID: 26485008 Free article. Clinical Trial.
[Importation dengue].
Mele P, Marroni M, Di Candilo F, Moretti MV, Stagni G. Mele P, et al. Among authors: di candilo f. Recenti Prog Med. 2001 Jan;92(1):37-9. Recenti Prog Med. 2001. PMID: 11260967 Italian.
Entecavir to treat severe acute hepatitis B.
De Socio GV, Mercuri A, Di Candilo F, Baldelli F. De Socio GV, et al. Among authors: di candilo f. Scand J Infect Dis. 2009;41(9):703-4. doi: 10.1080/00365540903062705. Scand J Infect Dis. 2009. PMID: 19544224 No abstract available.
19 results